What question did this study set out to answer?

Quantifying the population-level impact of delayed access to trastuzumab deruxtecan for patients with HER2-low metastatic breast cancer in Brazil.

Access to trastuzumab deruxtecan for HER2-low metastatic breast cancer in Brazil’s Unified Public Health System: A population-impact model.

View Full Paper

Ask AI

Bookmark

Authors

Population-impact analysis reveals significant preventable deaths from delayed access to trastuzumab deruxtecan in Brazil.

Quantifying the population-level impact of delayed access to trastuzumab deruxtecan for patients with HER2-low metastatic breast cancer in Brazil.
Nationwide population-impact analysis from the public-payer perspective.
Combined Brazilian epidemiologic data with survival benefit estimates from randomized clinical trials.
Modeling long-term outcomes under delayed-access scenarios using exponential approximation.
Estimated 656 preventable deaths/year with 95% uptake among 1,821 treated patients.
Over 10 years, 6,560 deaths avoided, translating to 9,713 life-years gained under the same uptake scenario.
Sensitivity analysis indicates a range of 255-947 preventable deaths/year based on varying HER2-low prevalence.

Yabrude et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark